Видео ютуба по тегу Valor-Hcm

Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition
Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition
AHA 24: VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy
AHA 24: VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy
HCM alto en sangre: ¿qué significa?
HCM alto en sangre: ¿qué significa?
Episode 5 - HCM Update, part 1, Diagnosis, Testing, and Patient Perspective
Episode 5 - HCM Update, part 1, Diagnosis, Testing, and Patient Perspective
Episode 6 - HCM Update, part 2 - Management and New Therapies
Episode 6 - HCM Update, part 2 - Management and New Therapies
ACC CVRI: Journal Club: VALOR-HCM Trial - By Tess Calcagno
ACC CVRI: Journal Club: VALOR-HCM Trial - By Tess Calcagno
Drug Reduces the Need for Surgery in Nearly 90% of Patients with HCM, Cleveland Clinic Study Shows
Drug Reduces the Need for Surgery in Nearly 90% of Patients with HCM, Cleveland Clinic Study Shows
After Shocks with Dr. Milind Desai on the VALOR-HCM trial
After Shocks with Dr. Milind Desai on the VALOR-HCM trial
VALOR-HCM Shows Promise for Patients With Hypertrophic Cardiomyopathy (for Healthcare Professionals)
VALOR-HCM Shows Promise for Patients With Hypertrophic Cardiomyopathy (for Healthcare Professionals)
Discussing the VALOR-HCM Trial
Discussing the VALOR-HCM Trial
VALOR-HCM: Mavacamten in Obstructive Hypertrophic Cardiomyopathy
VALOR-HCM: Mavacamten in Obstructive Hypertrophic Cardiomyopathy
ACC 22: Findings from the VALOR-HCM Trial | Dr Milind Y Desai
ACC 22: Findings from the VALOR-HCM Trial | Dr Milind Y Desai
ESC TV at #ACC22 - Expert Insights on VALOR-HCM and MAVA-LTE Study
ESC TV at #ACC22 - Expert Insights on VALOR-HCM and MAVA-LTE Study
VALOR-HCM - mavacamten para Cardiomiopatia Hipertrófica
VALOR-HCM - mavacamten para Cardiomiopatia Hipertrófica
La SEC te lleva a ACC22 [IN] ∙ VALOR-HCM
La SEC te lleva a ACC22 [IN] ∙ VALOR-HCM
Clinical Trial Shows Drug is Effective in Nearly 80% of Patients with Hypertrophic Cardiomyopathy
Clinical Trial Shows Drug is Effective in Nearly 80% of Patients with Hypertrophic Cardiomyopathy